OmniAb, Inc.
NNASDAQ:OABICapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew William Foehr
- Full Time Employees
- 89
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 5980 Horton Street Emeryville CA United States 94608
- IPO Date
- Oct 9, 2020
- CIK
- 0001846253
- Website
- omniab.com
- Similar Companies
- Business
- OmniAb, Inc. (OABI) is a biotechnology company that licenses proprietary transgenic animal platforms and discovery technologies to pharmaceutical, biotechnology and academic partners worldwide to enable the discovery of next-generation antibody-based therapeutics. The company offers a suite of genetically engineered animals including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic and OmniTaur for generating fully human or humanized antibodies; OmnidAb for single-domain antibodies; high-throughput single B-cell screening via the xPloration platform; and OmniDeep computational tools leveraging AI and machine learning for antibody optimization, with applications spanning bispecific biologics, antibody-drug conjugates, CAR-T therapies, radiotherapeutics and ion channel/transporter targets. Founded in 2012 and headquartered in Emeryville, California, OmniAb operates globally with over 100 active partners, 95 of which support 378-399 programs including 32-33 in clinical development or commercialization as of early 2025. Recent developments include the May 2025 launch of the xPloration Partner Access Program allowing partners to purchase the screening instrument for in-house use; a research collaboration and license with Orion Corporation for an ion-channel target offering over $55 million in milestones; an asset sale to Angelini Pharma for a Kv7.2 program with $3 million upfront and over $170 million potential milestones; a co-discovery alliance with VERAXA Biotech for bispecific antibody-drug conjugates; a November 2025 technology license and services agreement with Mabtrx Biosciences using OmnidAb technology for equity, services revenue and royalties; and an August 2025 $30 million private placement to bolster liquidity and corporate purposes.
Company News
OmniAb: A Self-Funding Option Book On 433 Partner Programs
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
OmniAb Q3 Earnings Call Highlights
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
OmniAb to Report Third Quarter 2026 Financial Results on October 30
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Bank of America Corp DE Acquires 149,493 Shares of OmniAb, Inc. $OABI
OmniAb to Host Investor & Analyst Day on October 6, 2026
OmniAb to Participate in Upcoming Investor Conferences
OmniAb to Participate in Upcoming Investor Conferences
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
OmniAb Raises 2026 Financial Guidance
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company